文献速递糖尿病

糖尿病患者早期血压控制与心血管疾病发病的关联

Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes.
PubMed 文献 · Diabetes Care · 2019-01-01

该回顾性队列研究纳入43,986例2002–2007年新启动降压治疗的糖尿病患者,按治疗前及治疗2年后收缩压(SBP)分层,分析早期SBP与动脉粥样硬化性心血管疾病(ASCVD)事件的关联。结果显示,治疗前SBP 130–139 mmHg且治疗后SBP<130 mmHg者ASCVD风险更低。

要点

  • 治疗前SBP≥140 mmHg者较130–139 mmHg者ASCVD风险更高(HR 1.10)。
  • 治疗前SBP 130–139 mmHg且治疗后SBP 120–129 mmHg者ASCVD发生率最低。
  • 治疗后SBP 130–139 mmHg者ASCVD发生率高于治疗后120–129 mmHg者。

核心结论

  • 糖尿病患者启动降压治疗时SBP为130–139 mmHg且治疗2年后SBP<130 mmHg者,ASCVD结局优于启动时或治疗后SBP更高者。

研究设计与样本

  • 观察性队列研究,纳入43,986例2002–2007年间新启动降压治疗的糖尿病患者。
  • 按治疗前SBP(130–139或≥140 mmHg)及治疗2年后SBP(100–119、120–129、130–139、140–159、≥160 mmHg)分层。
  • 主要结局为复合ASCVD事件(致死性和非致死性心肌梗死及卒中),采用逆概率治疗加权泊松回归和多变量Cox比例风险回归估计。

主要发现

  • 与治疗前SBP 130–139 mmHg者相比,治疗前SBP≥140 mmHg者ASCVD风险更高(HR 1.10 [95% CI 1.02, 1.19])。
  • 以治疗前SBP 130–139 mmHg且治疗后SBP 120–129 mmHg为参照,治疗前SBP≥140 mmHg且治疗后SBP 120–129 mmHg者ASCVD发生率更高(调整IRD 1.0 [-0.2 to 2.1] events/1,000 person-years)。
  • 治疗后SBP 130–139 mmHg者ASCVD发生率更高:治疗前SBP 130–139 mmHg者IRD 1.9 [0.6, 3.2] events/1,000 person-years,治疗前SBP≥140 mmHg者IRD 1.1 [0.04, 2.2] events/1,000 person-years。

临床怎么用

  • 对糖尿病患者启动降压治疗时,可考虑将SBP 130–139 mmHg作为启动阈值之一,并将治疗后SBP控制在<130 mmHg以降低ASCVD风险。
  • 治疗2年后SBP仍处于130–139 mmHg者ASCVD风险仍高于SBP 120–129 mmHg者,提示需强化随访期血压管理。

局限性

  • 本研究为观察性研究,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guidelines for hypertension treatment in patients with diabetes diverge regarding the systolic blood pressure (SBP) threshold at which treatment should be initiated and treatment goal. We examined associations of early SBP treatment with atherosclerotic cardiovascular disease (ASCVD) events in U.S. adults with diabetes. RESEARCH DESIGN AND METHODS: We studied 43,986 patients with diabetes who newly initiated antihypertensive therapy between 2002 and 2007. Patients were classified into categories based on SBP at treatment initiation (130-139 or ≥140 mmHg) and after 2 years of treatment (100-119, 120-129, 130-139, 140-159, and ≥160 mmHg). The primary outcome was composite ASCVD events (fatal and nonfatal myocardial infarction and stroke), estimated using inverse probability of treatment-weighted Poisson regression and multivariable Cox proportional hazards regression. RESULTS: Relative to individuals who initiated treatment when SBP was 130-139 mmHg, those with pretreatment SBP ≥140 mmHg had higher ASCVD risk (hazard ratio 1.10 [95% CI 1.02, 1.19]). Relative to those with pretreatment SBP of 130-139 mmHg and on-treatment SBP of 120-129 mmHg (reference group), ASCVD incidence was higher in those with pretreatment SBP ≥140 mmHg and on-treatment SBP 120-129 mmHg (adjusted incidence rate difference [IRD] 1.0 [-0.2 to 2.1] events/1,000 person-years) and in those who achieved on-treatment SBP 130-139 mmHg (IRD 1.9 [0.6, 3.2] and 1.1 [0.04, 2.2] events/1,000 person-years for those with pretreatment SBP 130-139 mmHg and ≥140 mmHg, respectively). CONCLUSIONS: In this observational study, patients with diabetes initiating antihypertensive therapy when SBP was 130-139 mmHg and those achieving on-treatment SBP <130 mmHg had better outcomes than those with higher SBP levels when initiating or after 2 years on treatment.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Raghavan S, Ho YL, Kini V, et al. Association Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With Diabetes. Diabetes Care. 2019. PMID: 31515207. doi:10.2337/dc19-0686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。